Subjects were treated with ronacaleret @mg ( n = @ ) , @mg ( n = @ ) , @mg ( n = @ ) , or @mg ( n = @ ) once daily , alendronate @mg ( n = @ ) once weekly , or matching placebo ( n = @ ) for @-@months ; BMD was measured after discontinuation of ronacaleret or alendronate treatment .